Therapy Areas: Vaccines
Global Virus Filtration Market to Reach USD 6.1bn by 2025 Research and Markets Forecasts
26 October 2017 - - The global virus filtration market is expected to reach USD 6.1bn by 2025, according to a new report from Dublin-based Research and Markets.

The market is expected to witness a CAGR of 12.5% over the forecast period, increasing demand for biological products such as vaccines, therapeutic proteins, blood and blood products, cellular and gene therapy, tissue, and stem cell products is a major factor driving market growth.

Biopharmaceuticals are mainly derived from human, animal, and plants and therefore require a scrutinized virus filtration procedure to avoid virus contamination in the production.

Therefore, the necessity of this procedure during the production of biologics is expected to boost the market growth.

Many leading biopharmaceuticals and biotechnology manufacturers are involved in R and D to develop innovative biological products.

For instance, in 2016, Pfizer Inc. invested 7,872.0 m in R and D, which was around 8% more than the R and D investment in 2015.

This investment was mainly undertaken to boost innovation and productivity in R and D to accomplish a sustainable pipeline of vaccines and differentiated therapies with lucrative commercial opportunities.

Virus filtration is an important step in biologics development, thus, the increasing R and D on biologics is expected to drive the demand for these products.

The consumables segment was the largest revenue generating segment of the market in 2016 owing to the increased usage of consumables including reagents, kits, and membranes in biologics downstream processing.

In the technology segment, the chromatography segment is projected to grow at the highest growth rate during the forecast period.

This is because of product advancements such as disposable or single-use membranes that eliminate the risk of a potential virus contaminant.

The biologicals segment accounted for the largest share of the market and is projected to maintain its dominance during the forecast period due to rising prevalence of chronic diseases such as cancer, blood disorders, and diabetes.

The biopharmaceutical and biotechnology companies segment is projected to grow at the highest CAGR during the forecast period because of increasing investment in R and D and production of biologics.
North America dominated the overall market in 2016 primarily due to the presence of several leading biotechnology companies and increased R and D activities for the development of biologics.

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. Growing presence of CROs in Asia Pacific countries including China and India due to the presence of a large genome pool, less stringent regulations, and availability of economical labor force is contributing to the growth of this region.

Some of the major players are Merck KGaA; Sartorius; Danaher; Thermo Fisher Scientific, Inc.; Charles River Laboratories International, Inc.; GE Healthcare; Asahi Kasei Medical Co., Ltd.; WuXi PharmaTech (Cayman) Inc.; Lonza; and Clean Cells.
Login
Username:

Password: